98%
921
2 minutes
20
Purpose: We present an optimized intraoperative spectrally encoded coherence tomography and reflectometry (iSECTR) system integrated with a Zeiss OPMI VISU 200 ophthalmic surgical microscope (Zeiss, Oberkochen, Germany).
Methods: An iSECTR scan-head was designed to overcome previous barriers to clinical translation by improving system stability, optimizing optical throughput, reducing reflection artifacts, and adding motorized focus-adjust functionality. The iSECTR imaging performance was demonstrated in in vivo human eyes and during simulated ophthalmic surgical maneuvers in ex vivo porcine eyes.
Results: The optimized iSECTR scan-head achieved a footprint of 19.67 × 30.2 cm (width × length) and a surgical microscope stack height increase of only 6.06 cm. Motorized focusing was able to accommodate for ±10 D of focal shift to accommodate refractive power differences across surgeons. In vivo and ex vivo iSECTR imaging was able to resolve clinically relevant retinal and corneal tissue features and tissue deformation from conventional surgical instruments during simulated ophthalmic surgical maneuvers.
Conclusions: This work demonstrates the performance of our iSECTR scan-head for ophthalmic intraoperative optical coherence tomography (iOCT). Our robust modular design allows for stable performance that is suitable for clinical translation. The improved spectrally encoded reflectometry (SER) imaging performance allowed for reproducible anterior and posterior eye imaging in both in vivo and ex vivo eyes, and independent iSECTR focus-adjust further enhances clinical ergonomics. Clinical translation of iSECTR technologies will provide a research platform for automated retinal- and instrument-tracking and four-dimensional visualization of surgical dynamics.
Translational Relevance: Design considerations for minimizing footprint, microscope stack height, and integration of motorized focus-adjust were emphasized to benefit surgical ergonomics and clinical translation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302043 | PMC |
http://dx.doi.org/10.1167/tvst.14.7.13 | DOI Listing |
Cureus
August 2025
Ophthalmology, Cornea and Refractive Surgery, John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, USA.
Purpose This study aims to compare the initial three-month outcomes of a single-center experience with small incision lenticule extraction (SMILE) for correction of myopia and myopic astigmatism using the VisuMax 500 (Carl Zeiss Meditec, Jena, Germany) versus the VisuMax 800 (SMILE Pro®; Carl Zeiss Meditec, Jena, Germany). This experience is compared to the US Food and Drug Administration approval studies and published literature. Patients and methods The initial 45 eyes (23 patients) that underwent SMILE with the VisuMax 500 in 2018 were compared with the initial 42 eyes (21 patients) that underwent SMILE Pro® with the VisuMax 800 in 2024.
View Article and Find Full Text PDFOral Maxillofac Surg
September 2025
Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University, Shinmachi 2-5-1, Hirakata-city, Osaka, Japan.
Purpose: For submandibular gland resection, conventional surgery with the naked eye remains the standard. With its excellent automatic focus and high magnification, the ORBEYE 3D exoscope enables precise submandibular gland resection with less stress. Therefore, we aimed to examine the usefulness of the exoscope in submandibular gland resection.
View Article and Find Full Text PDFNat Aging
September 2025
Aging Biomarker Consortium (ABC), Beijing, China.
The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age-related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual's physiological and molecular state, across diverse Chinese cohorts.
View Article and Find Full Text PDFOphthalmic Plast Reconstr Surg
September 2025
Department of Ophthalmology, Bascom Palmer Eye Institute.
Purpose: The primary objective was to investigate the trends in orbital exenteration rates at a large tertiary care center, particularly in the context of recent advancements in immunotherapy, targeted agents, and globe-sparing surgical techniques, which have significantly impacted patient management.
Methods: We conducted a retrospective cohort study at the University of Miami. Patients who underwent orbital exenterations from 2011 to 2024 were identified by obtaining surgical coding data via institutional data brokers and validated through a rigorous surgical chart review.
Ophthalmic Plast Reconstr Surg
September 2025
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, U.S.A.
This study aimed to report clinical outcomes of topical chemotherapy for ocular adnexal sebaceous carcinoma (OaSC) with intraepithelial spread. A retrospective chart review of patients with OaSC treated at the Bascom Palmer Eye Institute between 2000 and 2023 was conducted. Patient inclusion criteria included: (1) biopsy-proven diagnosis of OaSC, (2) intraepithelial pagetoid involvement confirmed by conjunctival map biopsy, (3) implementation of topical chemotherapy for tumor control, and (4) repeat conjunctival map biopsy following cessation of topical chemotherapy.
View Article and Find Full Text PDF